- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00305760
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Erbitux (Cetuximab) for the Treatment of Advanced Pancreatic Adenocarcinoma
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with cyclophosphamide and cetuximab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well vaccine therapy works when given together with cyclophosphamide and cetuximab in treating patients with metastatic or locally advanced pancreatic cancer.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Determine the safety of pancreatic tumor vaccine, cyclophosphamide, and cetuximab in patients with metastatic or locally advanced adenocarcinoma of the pancreas.
Secondary
- Determine the overall, progression-free, and event-free survival of patients treated with this regimen.
- Correlate specific in vivo parameters of immune response (e.g., mesothelin, prostate stem cell antigen [PSCA], mutated k-ras-specific T-cell responses) with clinical response in patients treated with this regimen.
- Correlate downstream targets of epidermal growth factor receptor (EGFR) signaling (e.g., intratumor expression of Akt, Stat 3 and 5, mesothelin, mutated k-ras, and PSCA) with inhibition by cetuximab in patients treated with this regimen.
- Correlate inhibition of EGFR signaling (e.g., Stat 3 and 5) with improved specific mesothelin, PSCA, and mutated k-ras-specific T-cell responses in patients treated with this regimen.
OUTLINE: This is an open-label study.
Patients receive cyclophosphamide IV on day 0, sargramostim plasmid DNA pancreatic tumor vaccine intradermally on day 1, and cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection and tumor biopsies periodically during study for biomarker correlative studies.
At the completion of study treatment, patients are followed at 3 weeks and then every 4 weeks for 16 weeks.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically confirmed ductal adenocarcinoma of the pancreas
- Mixed adenocarcinoma tumors eligible provided the predominant invasive component of the tumor is adenocarcinoma
The following histologic diagnoses are not eligible:
- Adenosquamous
- Squamous cell
- Colloid
- Islet cell
- Serous or mucinous cystadenoma or cystadenocarcinoma
- Carcinoid
- Small or large cell carcinoma
- Intraductal oncocytic papillary neoplasms
- Osteoclast-like giant cell tumors
- Acinar cell carcinoma
- Pancreatoblastoma
- Solid pseudopapillary tumors
- Undifferentiated small cell carcinoma
- Nonepithelial tumors (sarcoma, gastrointestinal stromal tumor, lymphoma)
- Adenocarcinomas of the ampulla, distal bile duct, or duodenum
- Metastatic or locally advanced disease that is refractory to standard therapy OR for which patient refused standard therapy
Measurable disease defined as ≥ 1 lesion unidimensionally measured as ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan
No nonmeasurable disease only including, but not limited to, the following:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural or pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Abdominal masses that are not confirmed and followed by imaging techniques
- Cystic lesions
- No known active or untreated brain metastases
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- WBC ≥ 3,500/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Hemoglobin ≥ 9 g/dL
- Platelet count ≥ 90,000/mm^3
- Creatinine ≤ 2.0 mg/dL
- Bilirubin ≤ 2 mg/dL
- ALT and AST ≤ 5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 5 times ULN
- No active infection
- No uncontrolled medical condition that would potentially increase the risk of toxicities or complications of study therapy
- No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
- No active peptic ulcer disease
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 4 weeks after completion of study treatment
- No other malignancy within the past 5 years except for nonmelanomatous skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix
- HIV negative
No active autoimmune disease or prior autoimmune disease requiring medical treatment with systemic immunosuppressants including any of the following:
- Inflammatory bowel disease
- Systemic vasculitis
- Scleroderma
- Psoriasis
- Multiple sclerosis
- Hemolytic anemia or immune thrombocytopenia
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Sjögren's syndrome
- Sarcoidosis
- Asthma or chronic obstructive pulmonary disease that does not require systemic corticosteroids or routine use of inhaled steroids allowed
- No known or suspected hypersensitivity to sargramostim (GM-CSF), cyclophosphamide, pentastarch, corn, or DMSO
- No prior severe infusion reaction (> grade 3) to a monoclonal antibody
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 1 month since prior adjuvant chemotherapy
- More than 4 weeks since prior surgery except for minor procedures (e.g., dental work, skin biopsy) and biliary stent placement
- No prior surgical procedures affecting absorption
- More than 4 weeks since prior radiotherapy
- More than 1 month since prior participation in an investigational new drug study
- No unresolved chronic toxicity (except alopecia) from prior anticancer therapy
- More than 28 days since prior systemic steroids
No concurrent systemic steroids or immunosuppressive drugs
- Topical, inhaled, and intra-articular steroids allowed
- No other concurrent anticancer vaccine therapy
- No other concurrent chemotherapy, immunotherapy, radiotherapy, gene therapy, biologic therapy, or investigational therapy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Cyclophosphamide, Pancreatic Tumor Vaccine, Cetuximab
|
Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
Andere Namen:
Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
Andere Namen:
Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse Events Observed in Greater Than 5% of the Patient Population
Zeitfenster: 7 months
|
7 months
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Neubildungen
- Neubildungen nach Standort
- Erkrankungen des endokrinen Systems
- Neoplasmen des Verdauungssystems
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Neoplasmen der Bauchspeicheldrüse
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antirheumatika
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Myeloablative Agonisten
- Antineoplastische Mittel, immunologische
- Cyclophosphamid
- Impfungen
- Cetuximab
Andere Studien-ID-Nummern
- J0501
- P30CA006973 (US NIH Stipendium/Vertrag)
- BMS-CA225247
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRekrutierungKopf-Hals-Plattenepithelkarzinom | MargenbewertungNiederlande
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenBeendetMetastasierter DarmkrebsNiederlande
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRekrutierungDickdarmkrebs | Capecitabin | CetuximabChina
-
Eben RosenthalNational Cancer Institute (NCI)BeendetAdenokarzinom des PankreasVereinigte Staaten
-
HiberCell, Inc.BeendetDarmkrebsVereinigte Staaten, Puerto Rico, Deutschland, Frankreich
-
Merck KGaA, Darmstadt, GermanyAbgeschlossenZuvor unbehandelter metastasierter DarmkrebsFrankreich, Italien, Polen, Deutschland, Hongkong, Österreich, Brasilien, Israel, Griechenland, Argentinien, Thailand, Belgien, Australien, Mexiko
-
Merck KGaA, Darmstadt, GermanyAbgeschlossenNicht-kleinzelliger Lungenkrebs (NSCLC)Deutschland
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCAbgeschlossen
-
Cancer Institute and Hospital, Chinese Academy...Rekrutierung
-
Universitaire Ziekenhuizen KU LeuvenMerck KGaA, Darmstadt, GermanyAbgeschlossenDarmkrebsSpanien, Frankreich, Belgien, Ungarn, Österreich